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Acute lymphoblastic leukemia (ALL) is the most 
common form of cancer in children, accounting for 
approximately 25% of all childhood cancers. Treatment 
of pediatric ALL represents one of the success stories of 
modern medicine, with 5-year survival exceeding 90% 
[1]. Improved outcome can be attributed to risk-stratified 
therapy and the discovery of targeted agents. Despite such 
advances, a significant proportion of high-risk patients, 
such as infants with KMT2A gene rearrangements and 
children with BCR-ABL fusion, continue to have an 
inferior prognosis [2]. Although treatment protocols have 
increased the intensity of conventional chemotherapy to 
improve survival, chemotherapeutic drugs do not spare 
healthy normal cells and a plateau has been reached; 
recent years have seen little improvement in outcome 
due to an increase in toxic death and the recognition of 
increased morbidity in survivors due to the development 
of significant late effects. 
Novel therapeutic strategies provide much 
promise to further combat childhood leukemia. Over 
the past decade, the striking rise of immunotherapies 
has revolutionized treatment for cancer. Immunotherapy 
has reached a groundbreaking milestone, with the FDA 
approving three immunotherapies for certain indications 
in pediatric and adult ALL in 2017 [3], with many others 
under continued development. 
Another novel therapeutic strategy that remains 
primed for investigation is targeting of the tumor 
microenvironment. Recognition that the tumor 
microenvironment contributes to treatment failure or 
success has led to a paradigm shift [4]. While extensive 
research has identified that the microenvironment of 
solid tumors plays a key role in multiple stages of cancer 
progression, relapse, immune-escape and metastasis, 
the importance of the leukemia microenvironment 
has only recently been appreciated. Studies in acute 
myeloid leukemia have demonstrated that normalization 
of the bone marrow microenvironment reduces disease 
progression, validating the microenvironment as a new 
therapeutic target for patients with leukemia [5]. 
Changes within the bone marrow microenvironment 
have been described in patients with ALL (Figure 1). 
This includes lower serum markers of bone formation 
prior to initializing therapy, reduction in trabecular bone 
volume and thickness, as well as lower percentages of 
adipocytes, osteoblasts and osteoclasts [6–8]. However, 
the impact of ALL on hematopoiesis and the bone marrow 
microenvironment remains unclear. In a recent study, 
we characterized the bone marrow microenvironment 
in pre-B ALL using an immunocompetent BCR-ABL1+ 
model [9]. Leukemia development was shown to perturb 
B-lymphopoiesis and myelopoiesis, suggesting that 
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Figure 1: Schematic representation of normal versus the pre-B acute lymphoblastic leukemia bone marrow 
microenvironment. In normal hematopoiesis, hematopoietic stem cells are surrounded by stromal cells in the microenvironment 
including osteoblasts, osteoclasts and adipocytes. In contrast, invasion of leukemia cells results in osteopenia as well as a reduction in 
osteoblast and adipocyte number. RANKL, produced by leukemia cells, is responsible for osteoclast-mediated bone resorption.
Oncotarget1757www.oncotarget.com
leukemogenesis alters the activity of hematopoietic stem 
and progenitor cells. Furthermore, reduced numbers of 
osteoblasts and enhanced activity of osteoclasts contribute 
to the homeostatic imbalances of bone during leukemia 
development, recapitulating the clinical features of bone 
loss in children with ALL. A high level of RANKL 
secreted by leukemia cells was identified as being 
responsible for the osteoclast-mediated bone loss (Figure 
1). 
To test whether targeting of the bone marrow 
microenvironment reduced progression of pre-B ALL, 
the effect of an osteoclastic inhibitor, zoledronic acid, was 
investigated. Zoledronic acid has been used as an adjuvant 
therapy for treating advanced adult cancers with bone 
metastases and has been well tolerated when administered 
to children with ALL for treatment of osteonecrosis [10]. 
Treatment not only inhibited the activity of osteoclasts and 
restored bone loss but also hindered leukemia progression 
and prolonged survival. 
In summary, our findings shed light on the 
mechanisms of leukemia-induced bone loss and provide 
evidence for targeting the pathological interplay within the 
leukemia microenvironment as a novel therapeutic strategy 
for patients with pre-B ALL. Further studies evaluating the 
efficacy of zoledronic acid in combination with standard 
chemotherapy for pre-B ALL are now warranted.
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